Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer (ORCA-2)
A Phase I Trial of Olaparib in Addition to Cisplatin-based Concurrent Chemoradiotherapy for Patients With High Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (NHSCC)
Sponsor: AstraZeneca
A PHASE1 clinical study on Head and Neck Cancer, this trial is ongoing. The trial is conducted by AstraZeneca and has accumulated 13 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
Jan 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE1
-
Jun 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 8 earlier versions
-
Dec 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE1
-
Nov 2021 — Dec 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Apr 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Apr 2020 [monthly]
Recruiting PHASE1
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Sep 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Cancer Research UK
- University College, London
For direct contact, visit the study record on ClinicalTrials.gov .